Results 131 to 140 of about 28,829 (241)

Caspofungin versus anidulafungin in patients with invasive candidiasis: a retrospective study with propensity-score-matched analysis

Therapeutic Advances in Infectious Disease
Background: Echinocandins are recommended as an initial treatment for invasive candidiasis. Although safety and efficacy profiles of both anidulafungin and caspofungin are well established, direct head-to-head comparisons have not been reported before ...
Reem Hasan Elajez, Dana Bakdach, Sara Al Balushi, Ahmed Zaqout, Rand Alattar, Tasneem Abdallah, Waleed Awouda, Godwin Wilson, Walid Al-Wali, Emad Ibrahim, Hussam Alsoub   +10 more
doaj   +1 more source

Comparison of Vitek 2C antifungal susceptibility testing with broth microdilution testing for Candida species [PDF]

Medical Laboratory Journal
Background: The reference method for antifungal susceptibility testing is broth microdilution according to Clinical and Laboratory Standard Institute (CLSI) guidelines.
Sukanya Sudhaharan, Naga Appala Raju Sundarapu, Umabala Pamidimukkala   +2 more
doaj  

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients [PDF]

, 2017
Objectives Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants.
Akan, H., Ameye, L., Baila, L., Gallamini, A., Giagounidis, A., Herbrecht, R., Maertens, J., Marchetti, O., Martino, R., Meert, L., Paesmans, M., Shivaprakash, M., Sonet, A., Ullmann, A. J., Viscoli, C.   +14 more
core  

Caspofungin Combined With TMP/SMZ in Treatment of Intractable Acute Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients: Case Report and Literature Review

Clinical Case Reports
Pneumocystis jirovecii pneumonia (PJP) is a potential life‐threatening opportunistic infection that predominantly affects immunocompromised individuals, such as those with human immunodeficiency virus or organ transplant recipients. The treatment of PJP,
Hongtao Hu, Shen Xu, Wen Jiang, Baoping Xu, Jing Wang, Gang Xu   +5 more
doaj   +1 more source

Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America [PDF]

, 2017
Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America.
Andes, David, Benjamin, Daniel K., Calandra, Thierry F., Edwards, John E., Filler, Scott G., Fisher, John F., Kauffman, Carol A., Kullberg, Bart-Jan, Pappas, Peter G., Reboli, Annette C., Rex, John H., Sobe, Jack D., Walsh, Thomas J., Zeichner, Luis Ostrosky   +13 more
core  

Caspofungin

Reactions Weekly, 2021
Sujata Dwivedi, Shivaprakash M Rudramurthy   +1 more
openaire   +2 more sources

Repurposing caspofungin as a small-molecule inhibitor of Clostridium perfringens α-toxin for treatment of gas gangrene. [PDF]

Commun Med (Lond)
Takehara M, Homma Y, Ishihara T, Sakaguchi Y, Kasai Y, Matsumoto K, Nakashima K, Yamaji T, Tanaka Y, Imagawa H, Nagahama M.   +10 more
europepmc   +1 more source

Exploring Early Antifungal Activity of Rezafungin as a Stepping-Stone for Shorter Treatment Duration for Candidemia: Pooled Analysis of 2 Randomized Trials. [PDF]

Open Forum Infect Dis
Ostrosky-Zeichner L, Aram JA, Redell M, Thompson GR, Cornely OA, McKinnell JA, Spec A, Pappas PG.   +7 more
europepmc   +1 more source

Synergistic activity of caspofungin and posaconazole against <i>Candida</i> (<i>Candidozyma</i>) <i>auris</i> biofilms based on phenotypic, transcriptomic, and <i>in vivo</i> insights. [PDF]

Microbiol Spectr
Kovács F, Harmath A, Balázsi D, Forgács L, Ragyák Á, Balla N, Tóth Z, Bozó A, Borman AM, Majoros L, Kovács R, Jakab Á.   +11 more
europepmc   +1 more source

Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro. [PDF]

J Antimicrob Chemother
Abduljalil H, Bartie K, Bal AM, Rautemaa-Richardson R, Williams C, Kean R, Ramage G.   +6 more
europepmc   +1 more source